Angiogenesis in cancer: The role of endothelin-1

Annals of the Royal College of Surgeons of England

Volumn 81, Issue 5, 1999, Pages 306-310

  Dawas, K ^a   Loizidou, M ^a   Shankar, A ^a   Ali, H ^a   Taylor, I ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Endothelin 1

Indexed keywords

ENDOTHELIN 1; VASCULOTROPIN;

ANGIOGENESIS; CARCINOGENESIS; HUMAN; REVIEW; VASCULARIZATION;

EID: 0032822842     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Folkman J. Antiangiogenesis: new concept for therapy of solid tumours. Ann Surg 1972; 175: 409-16.
2. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
3. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995; 11: 73-41.
4. Shalaby F, Rossant J, Yamaguchi TP, Gertenstein M, Wu XF, Breitman ML et al. Failure of blood island formation and vasculogenesis in flk-1 deficient mice. Nature 1995; 376: 62-6.
5. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70.
6. Breier G, Risau W. The role of VEGF in blood vessel formation. Trends Cell Biol 1996; 6: 454-6.
7. Noden DM. In: Feinberger RN, Sherer GK, Auerbach R, eds. The Development of the Vascular System. Basel: Karger, 1991; 1-24.
8. Risau W. What, if anything, is an angiogenic factor? Cancer Mctast Rev 1996; 15: 149-51.
9. Short RHD. Alveolar epithelium in relation to growth of the lung. Philos Trans R Soc Loud B Biol Sci 1950; 235: 35-87.
10. Pardanaud L, Yassine F, Dieterlen-Lievre F. Relationship between vasculogenesis, angiogenesis and haematopoiesis during avian otogeny. Development 1989; 105: 473-85.
11. Ashton N. Oxygen and the growth and development of retinal vessels. Am J Ophthalmol 1966; 62: 412-35.
12. Resnick N, Gimbrone MA. Haemodynamic forces are complex regulators of endothelial gene expression. FASEB J 1995; 9: 874-82.
13. Burgess WH, Macaig T. The heparin binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989; 58: 575-606.
14. Ferrara N, Houck K, Jackman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
15. Folkman J. Tumour angiogenesis. In: Mendelsen J, Howley PM, Israel MA, Liotta LA eds. The Molecular Basis of Cancer. Philadelphia, PA: Saunders, 1995; 206-32.
16. Weidner N. Intratumour microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
17. Dameron KM, Volpert OV, Tainsky MA, Bouck N. control of angiogenesis in fibroblasts by p53 regulation of thromospondin-1. Science 1994; 265: 1582-4.
18. Harris AL. Anti-angiogenesis for cancer therapy. Lancet 1997; 349 (suppl 11): 13-5.
19. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis by colon cancer cells. Cell 1998; 93: 705-16.
20. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.
21. Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755-61.
22. Mlynek ML, van Beuningen D, Leder LD, Streffer C. Measurements of the grade of vascularisation in histological tumour tissue sections. Br J Cancer 1985; 52: 945-8.
23. Takebayashi Y, Akiyama S-I, Yamada K, Akiba S, Aikou T. Angiogenesis is an unfavourable prognostic factor in human colorectal carcinoma. Cancer 1996; 78: 226-31.
24. Weidner N, Semple JP, Welch WR, Folkman J. Tumour angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
25. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumour infarction in mice by antibody-directed targeting of tissue factor to tumour vasculature. Science 1997; 275: 547-50.
26. Pipili-Synetos E, Papageorgiou A, Sakkoula E, Sotiropoulo G, Fotsis T, Kaiakiulakis G et al. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 1995; 116: 1829-34.
27. Teicher BA, Holden SA, Ara G, Northey D. Potentiation of cytotoxic cancer therapy by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994; 57: 920-5.
28. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 1994; 46: 325-415.
29. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 1994; 25: 1135-43.
30. Miyauchi T, Yanagisawa M, Tomizausa T, Sugishita Y, Suzuki N, Fujino M et al. Increased plasma concentrations of endohelin-1 and big endothelin in acute myocardial infarction. Lancet 1989; ii: 53-4.
31. Kato T, Kassab S, Wilkins Jr FC, Kirchner KA, Keiser J, Granger JP. Endothelin antagonists improve renal function in spontaneously hypertensive rats. Hypertension 1995; 25: 883-7.
32. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantodosi S, Eisenberger MA et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1: 944-9.
33. Asham E, Loizidou M, Lakhani S, Miller K, Burnstock G, Boulos PB et al. Expression of endothelin-1 in 98 patients with colorectal cancer. Eur J Surg Oncol 1997; 23: 589.
34. Patel KV, Schrey MP. Human breast cancer cells contain a phosphoramidon-sensitive metalloproteinase which can process exogenous big endothelin-1 to endothelin-1: a proposed mitogen for human breast fibroblasts. Br J Cancer 1995; 71: 442-7.
35. Lin HY, Kaji EH, Winkel GK, Ives HE, Lodish HF. Coding and functional expression of a vascular smooth muscle endothelin-1 receptor. Proc Natl Acad Sci USA 1991; 88: 3185-9.
36. Pedram A, Razandi M, Hu R-M, Levin E. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 1997; 272: 17097-103.
37. Shichiri M, Hirata Y, Nakajima T, Ando K, Imai T, Yanagisawa M et al. Endothelin-1 is an autocrine / paracrine growth factor for human cancer cell lines. J Clin Invest 1991; 87: 1867-71.
38. Ziche M, Morbidelli M, Donnini S, Ledda F. ETB receptors promote proliferation and migration of endothelial cells. J Cardiovasc Pharmacol 1995; 26 (suppl 3): S284-6.
39. Shankar A, Loizidou M, Aliev G, Fredericks S, Holt D, Boulos PB et al. Elevated endothelin-1 production and secretion by cancer. Br J Surg 1996; 83: 1623-52.
40. Nakamuta M, Ohashi M, Tabata S, Tanabe Y, Goto K, Naruse M et al. High plasma concentrations of endothelin like immunoreactives in patients with hepatocellular carcinoma. Am J Gastroenterol 1993; 88: 248-52.
41. Zhao YD, Springall DR, Hamid Q, Levene M, Polak JM. Localisation and characterisation of endothelin-1 receptor binding in the blood vessels of human pulmonary tumours. J Cardiovasc Pharmacol 1995; 26 (suppl 3): S341-5.
42. 125I- endothelin-1 binding to human meningiomas and antagonises ET1-induced proliferation of meningioma cells. Cell Mol Neurobiol 1994; 14: 105-18.
43. Bagnato A, Tecce R, Dicastro V, Catt KJ. Activation of mitogenic signalling by endothelin-1 in ovarian carcinoma cells. Cancer Res 1997; 57: 1306-11.
44. Moraitis S, Langdon SP, Miller WR. Endothelin expression and responsiveness in human ovarian carcinoma cell lines. Eur J Cancer 1997; 33: 661-8.
45. Kusuhara M, Yamaguchi K, Nagasaki K, Hayashi C, Suzaki A, Hori S et al. Production of endothelin in human cancer cells. J Clin Invest 1990; 50: 3257-61.
46. Kusuhara M, Yamaguchi K, Ohnishi A, Abe K, Kimura S, Oona H et al. Endothelin potentiates growth factor stimulated DNA synthesis in Swiss 3T3 cells. Jpn J Cancer Res 1989; 80: 302-5.
47. Brown PD, Giavazz R. Matrix metalloproteinase inhibition - a review of anti-tumour activity. Ann Oncol 1995; 6: 967-74.
48. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shurren MA et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumour growth in syngeneic mice. Cancer Res 1996; 56: 2428-33.
49. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI et al. Inhibition of angiogenesis by recombinant platelet factor 4 and related peptides. Science 1996; 247: 77-9.
50. Zugmaier G, Lippman ME, Wellstein A. Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumour cells and blockage by PPS of tumour growth in animals. J Natl Cancer Inst 1992; 84: 1716-24.
51. Millauer B, Longhi MP, Plate KH, Stawver LK, Risav W, Ullrich A et al. Dominant-negative inhibition of flk-1 suppresses the growth of many tumour types in vivo. Cancer Res 1996; 56: 1615-20.
52. Ali H, Dashwood M, Loizidou M, Fredericks S, Steard C, Savage F et al. Endothelin a receptor antagonist affects growth of colorectal cancer cells. Eur J Surg Oncol 1988; 24: 622-3.
53. Boehm T. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Lancet 1997; 390: 404-7.